U.S. flag

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

  • Publications
  • Account settings
  • Advanced Search
  • Journal List
  • Wiley - PMC COVID-19 Collection

Logo of pheblackwell

Clinical presentation and management of COVID ‐19

Irani thevarajan.

1 Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne VIC

2 University of Melbourne, Melbourne VIC

Kirsty L Buising

Benjamin c cowie.

3 WHO Collaborating Centre for Viral Hepatitis, Doherty Institute, Melbourne VIC

  • The rapid spread of severe acute respiratory syndrome coronavirus 2 led to the declaration of a global pandemic within 3 months of its emergence.
  • The majority of patients presenting with coronavirus disease 2019 ( COVID ‐19) experience a mild illness that can usually be managed in the community. Patients require careful monitoring and early referral to hospital if any signs of clinical deterioration occur.
  • Increased age and the presence of comorbidities are associated with more severe disease and poorer outcomes.
  • Treatment for COVID ‐19 is currently predominantly supportive care, focused on appropriate management of respiratory dysfunction.
  • Clinical evidence is emerging for some specific therapies (including antiviral and immune‐modulating agents). Investigational therapies for COVID ‐19 should be used in the context of approved randomised controlled trials.
  • Australian clinicians need to be able to recognise, diagnose, manage and appropriately refer patients affected by COVID ‐19, with thousands of cases likely to present over the coming years.

In December 2019, a novel coronavirus emerged in Wuhan, Hubei Province, China, leading to a global pandemic. The virus, named severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), causes a clinical syndrome termed coronavirus disease 2019 (COVID‐19).

The first reports of an undiagnosed pneumonia in Wuhan on 8 December 2019 were followed by an alert from China to the World Health Organization (WHO) about a cluster of pneumonia cases on 30 December. Isolation of a novel coronavirus occurred on 3 January 2020. On 30 January, the WHO declared a public health emergency of international concern, and a pandemic was declared on 12 March 2020.

Clinical presentation

Similar to other coronaviruses, SARS‐CoV‐2 is predominantly spread by respiratory droplets, although spread by contact with contaminated fomites also occurs, as does transmission by aerosols in certain circumstances. 1

Based on the experience in China, the typical incubation period of COVID‐19 infection has been estimated to be a median of 5.1 days (95% CI, 4.5–5.8 days), with 97.5% of those who develop symptoms doing so within 11 days of exposure (95% CI, 8.2–15.6 days). This has informed the use of a 14‐day time period for quarantining potentially exposed individuals in an effort to limit onward spread. 2

The recognition of asymptomatic infection has been an area of intense interest in understanding the epidemiology of COVID‐19. The ratio of asymptomatic to symptomatic infection is currently uncertain. Cross‐sectional studies have reported asymptomatic infection in women attending a maternity service in New York (33 of 215 infected, 88% asymptomatic) 3 and in general population testing in Iceland (87 of 10 797 infected, 41% asymptomatic). 4 In such cross‐sectional studies, a proportion of those who were asymptomatic at the time of testing may in fact have been in the pre‐symptomatic phase of infection. In a study conducted in a nursing home in the United States, 48 of 76 residents tested positive, with 27 (56%) being asymptomatic at the time of testing. However, 24 (89%) of these individuals went on to develop symptoms at a median of 4 days (interquartile range [IQR], 3–5 days) after the positive test result. 5

Symptomatic COVID‐19 infection usually presents as a respiratory syndrome, most commonly with fever and cough. 6 , 7

Fever has been reported in up to 99% of people at some time during the course of their illness, but importantly in one cohort, it was reported to be present at the time of hospital presentation in only 44% of patients, and at some time during the hospital admission in 89%. 8 Other common symptoms are cough, dyspnoea, fatigue, anorexia, anosmia, myalgia and sometimes confusion. Diarrhoea may occur in up to 10% of patients. 9 Symptoms reported less frequently (< 5% of cases) include sore throat, rhinorrhoea, headache, chest pain, dizziness, abdominal pain and nausea. 6 , 7

Around 80% of COVID‐19 infections present as a mild respiratory illness in a patient who is ambulatory and can generally be managed outside the hospital. Around 15% typically need hospital care (usually for moderate to severe pneumonia), and another 5% have critical illness requiring more intensive supports. 10

Of those who require hospitalisation, the median time from first symptoms to onset of dyspnoea is 5 days (IQR, 1–10 days), the median time to hospital admission is 7 days (IQR, 4–8 days), and in those who develop more severe manifestations, the median time to acute respiratory distress syndrome is 8 days (IQR, 6–12 days). 6 About a quarter of patients who are hospitalised may need transfer to the intensive care unit (ICU) for the management of complications such as hypoxaemic respiratory failure or hypotension requiring vasopressor support. 11

At presentation to hospital, the most common laboratory feature of COVID‐19 infection is lymphopenia (reported in 70.3% of cases). 6 Radiological imaging may reveal a clear chest, unilateral or bilateral consolidation, or ground glass opacity.

Nasopharyngeal specimens, deep nasal swabs, throat swabs or lower respiratory samples (eg, sputum) sent for molecular detection of SARS‐CoV‐2 by polymerase chain reaction (PCR) are currently the best means of specific diagnosis of COVID‐19 in Australia. Faecal samples may also be PCR positive for COVID‐19 but the role of the oral–faecal route for transmission remains unclear. 12 Patients with more severe disease tend to have higher viral loads in respiratory samples. Mild cases have been shown to clear the virus earlier, with over 90% returning negative PCR test results by day 10 compared with severe cases who more often remain positive beyond day 10. 13 Viral loads appear to be highest early in the illness. Prolonged viral shedding after the onset of symptoms has been described. 14 The virus has also been detected by PCR in asymptomatic patients with comparable viral loads to those still symptomatic. 15

Patients with suspected or confirmed COVID‐19 should be assessed for features of severe disease and risk factors for progression to severe disease. This assists in determining whether a patient can safely be managed in the community or requires referral and admission to a health care facility able to provide acute inpatient care. Current data suggest that older patients and those with comorbidities have increased risk of progression to severe disease and mortality. In a large surveillance report from China including over 44 000 confirmed cases of COVID‐19, the case fatality rate was < 0.5% for patients aged < 50 years, but rose to 8.0% for those in their 70s, and 14.8% in those aged > 80 years. 16 While these surveillance‐based case fatality rates are possibly overestimates, being influenced by under‐recognition of lower severity cases, the impact of increasing age and the presence of comorbidities on risk of severe and fatal illness should be recognised, 8 and such patients should generally be offered more careful monitoring.

Clinical features that have been identified more often in COVID‐19 infected patients who have had a fatal outcome compared with those who survive are: dyspnoea at presentation (70.6% v 24.7%; P  < 0.001); lower initial oxygen saturation (median oxygen saturation, 85% [IQR, 75–91%] v 97% [IQR, 95–98%]; P  < 0.001); and higher total white blood cell count but lower lymphocyte count at presentation accompanied by a lower lymphocyte count, expressed as a lower lymphocyte percentage (median, 7.1% [IQR, 4.5–12.7%] v 23.5% [IQR, 15.3–31.3%]; P  < 0.001). 17 In developing a predictive model, Chinese researchers found four factors independently associated with disease progression during hospitalisation in 208 consecutive patients: presence of comorbidity, age > 60 years, lymphocyte count < 1.0 × 10 9 /L, and elevated lactate dehydrogenase levels. 18

A propensity for deterioration in the second week of illness has been recognised in some cohorts of patients, typically 5–10 days after the onset of symptoms. 19 All patients should be warned about symptoms of concern (such as increasing breathlessness), and early referral for hospital admission should be suggested for any patient with signs of clinical deterioration. Individual circumstances need to be considered when determining the ideal monitoring strategy and site of care for each patient ( Box ).

Assessing disease severity and consideration for setting of care for patients diagnosed with COVID‐19

Adapted from World Health Organization interim guidance, 21 Australasian Society for Infectious Diseases interim guidelines, 20 and National COVID‐19 Clinical Evidence Taskforce living guidelines. 19

General management

It is critically important to ensure optimal infection prevention from the time a patient with suspected COVID‐19 is first assessed until their infection is resolved, irrespective of the site of care. This can present particular challenges for health care staff, who must learn to use personal protective equipment safely, and for patients and their loved ones who must manage the difficulties associated with isolation.

Patients with mild disease (about 80%) 10 can often be managed in the community if they are able to self‐isolate. They must also be capable of monitoring their own condition, be aware of which symptoms should prompt medical review, and be able to escalate any concerns. 19 , 20 , 21 For some patients, a more proactive program of monitoring by phone or telehealth or in‐person monitoring (eg, hospital in the home, regular review by general practitioner, or hospital admission) may be required. Strategies for care should be individualised to suit patient circumstances. Patients whose home environment is not conducive to safe management, or which is unacceptable from an infection prevention perspective, may require admission either to hospital or to alternative safe accommodation. Discussion with public health authorities is essential to ensure that appropriate isolation and follow‐up mechanisms are in place. In the face of high health care demand during the peak of a pandemic, safe management of low risk patients in the community will likely be essential to preserve hospital capacity for the more severely ill.

Patients with moderate or severe illness will generally require admission to hospital. This includes those who are dyspnoeic on minor exertion, tachypnoeic at rest (respiratory rate > 22 breaths/min), hypoxaemic (pulse oximetry [SpO 2 ] < 94% on room air), hypotensive (systolic blood pressure < 100 mmHg), have an acutely altered mental state, or who have extensive pulmonary infiltrates evident on chest imaging. 19 , 20 , 21

Severe illness, indicated by, among other features, a respiratory rate > 30 breaths/min, SpO 2  < 92% on room air 19 , 21 or sustained hypotension, warrants urgent hospitalisation and consideration of the need for intensive care if suitable for a given patient.

Respiratory management

Supplemental oxygen should be administered for patients with SpO 2  < 92%. 19 , 20 Once stabilised, the target SpO 2 range is usually 92–96%. The target will be lower in those with chronic hypercapnoeic respiratory failure (eg, 88–92%). 19 , 20 , 21

Manoeuvres to improve gas exchange should be implemented, such as positioning patients appropriately in bed (on either side with regular turning), elevating the bed head to 30 degrees, encouraging deep breathing every hour while awake, sitting patients out of bed every day when possible, and mobilising when able. For mechanically ventilated patients with persistent hypoxaemia, prone positioning may be effective. 19 , 22

In the setting of progressive hypoxaemia despite low or moderate flow oxygen (via nasal prongs or Hudson mask), high flow oxygen can be considered. Whether high flow oxygen devices (> 10 mL/min) are potentially aerosol‐generating is being studied, but current guidelines 1 , 23 advise that airborne precautions be taken by staff (personal protective equipment including N95/P2 masks) and single rooms where possible.

There are emerging views that the respiratory dysfunction observed in COVID‐19 infections is not uniform. 22 Initial recommendations have focused on consideration of early intubation and mechanical ventilation for patients with acute respiratory distress syndrome due to COVID‐19. 1 , 19 , 20 , 21 Experience from a multicentre Italian COVID‐19 patient cohort suggests that non‐invasive ventilation such as continuous positive airways pressure and bilevel positive airways pressure may also have a role both within and outside ICUs. 24 These non‐invasive ventilation devices are clearly aerosol‐generating and as such should only be used with appropriate precautions in place. 1 , 23 Advice from experts in respiratory medicine or critical care should be sought.

Other management considerations

Empirical antibiotic therapy for bacterial pneumonia should be considered in patients whose illness is severe, where there is evidence of sepsis or septic shock, or where the patient is clinically deteriorating. 19 , 20 Empirical treatment for influenza with a neuraminidase inhibitor should be considered for patients with severe pneumonia (guided by local epidemiology) until influenza PCR results are available. 20 , 21 Empirical antibiotics are not recommended for patients with mild or moderate pneumonia unless there is additional clinical evidence to suggest bacterial infection. De‐escalation of empirical antimicrobial therapy should be undertaken as appropriate, guided by microbiology results (where available) and clinical judgement. 21

Hypovolaemia may be contributed to by reduced oral intake and increased losses, but management requires cautious administration of intravenous fluids with regular assessments given the risk of exacerbating pulmonary oedema in the setting of acute respiratory distress syndrome 19 , 22 and given the possibility of underlying cardiac injury. 25

A range of possible complications related to SARS‐CoV‐2 infection have been reported and their incidence is being monitored. These include thromboembolic events in the lungs 22 and cerebrovascular system, 26 Prophylaxis with anticoagulants for adults with moderate, severe or critical COVID‐19 infection is generally recommended, unless there are contraindications. 19 , 21 Acute cardiac injury presenting with electrocardiogram changes, arrhythmias, left ventricular dysfunction, cardiomyopathy and congestive cardiac failure have also been described, and assessment of baseline electrocardiogram is suggested for patients with moderate or severe COVID‐19 illness. 25 , 27

There is considerable interest in monitoring large patient cohorts and conducting analysis of linked datasets at a population level to establish whether there are any rare or longer term complications or associations of COVID‐19 with other medical conditions. Given the very recent emergence of SARS‐CoV‐2, data are currently limited but it is likely that information will emerge in coming months from populations that have experienced a high attack rate. An example of a rare condition with potential association is paediatric inflammatory multisystem syndrome temporally associated with SARS‐CoV‐2, presenting as hyperinflammatory shock with features similar to atypical Kawasaki disease. 28 Similarly, there is interest in monitoring long term incidence of cardiovascular complications, thromboembolic disease, chronic respiratory dysfunction, renal or neurological disorders, and post‐infectious inflammatory syndromes after COVID‐19, in addition to inspection of large datasets for complications that are as yet unsuspected.

Specific therapies

A range of pharmacotherapies have been proposed as possible treatments for COVID‐19. Early evidence of clinical benefit for some agents has emerged. The WHO interim guidance on the clinical management of COVID‐19 21 asserts that investigational therapeutics should be used only in approved randomised controlled trials. This position is endorsed by the Australasian Society for Infectious Diseases interim guidelines for the clinical management of COVID‐19 in adults, 20 and the Australian guidelines for the clinical care of people with COVID‐19, 19 which state that even where conditional recommendations for use of disease modifying agents are made, whenever possible these should be administered in the context of randomised trials with appropriate ethical approval.

The understandable interest in evaluating potential treatments has led to a large number of clinical trials being registered globally; by late April 2020, over 1100 clinical studies were registered, including over 500 randomised controlled trials. 29

Antimicrobials

Lopinavir–ritonavir.

Lopinavir–ritonavir, a combined antiretroviral agent, was proposed as a potential treatment for severe acute respiratory syndrome in 2003, based on apparent reductions in mortality in preliminary research in Hong Kong. 30 Given its hypothesised role, five of the first 18 patients diagnosed with COVID‐19 in Singapore were administered this agent. 31

On 18 March 2020, a randomised controlled open label trial of lopinavir–ritonavir in 199 hospitalised adults with COVID‐19 in China was published. 32 No benefit was observed in participants treated with the antiviral compared with controls. Nearly 14% of those receiving lopinavir–ritonavir were unable to complete 14 days of treatments owing to adverse events.

Chloroquine and hydroxychloroquine

Chloroquine and hydroxychloroquine are antimalarial agents which also have immunomodulatory properties that led to established indications for use in the treatment of rheumatological conditions. Potential adverse effects include retinal toxicity, QT interval prolongation and other cardiological and dermatological effects.

In early February 2020, chloroquine was reported to inhibit SARS‐CoV‐2 replication in vitro. 33 By mid‐February, treatment of COVID‐19 with chloroquine was being described as a “breakthrough”: a published letter stated that the results of treatment in over 100 patients in China had demonstrated that chloroquine was “superior to the control treatment”, but no data were provided. 34 A small French open label non‐randomised clinical trial examining hydroxychloroquine with or without azithromycin suggested a significant viral load reduction in those receiving therapy; 35 however, concerns have been raised about the design and analysis of the study. 36

Despite the lack of clinical evidence from randomised clinical trials, several institutional and local guidelines, and notable public figures, have supported the potential use of chloroquine or hydroxychloroquine for the treatment of COVID‐19. 37 , 38

However, given the current lack of evidence of clinical benefit and reports of significant limitations of supply of hydroxychloroquine for patients with rheumatological conditions, in March 2020, the Pharmaceutical Society of Australia and the Australasian Society for Infectious Diseases called for immediate cessation of prescribing and dispensing of hydroxychloroquine for indications relating to COVID‐19, outside use in approved clinical trials. 39 , 40

On 5 June 2020, the chief investigators on the RECOVERY trial (comprising over 11 500 patients enrolled from hospitals across the United Kingdom) issued a press release stating that no beneficial effect of hydroxychloroquine had been observed. 41 No difference in 28‐day mortality, duration of admission, or other outcomes were observed between the 1542 patients randomised to hydroxychloroquine and the 3132 patients randomised to usual care. Further details regarding this analysis are awaited.

In January 2020, the first patient diagnosed with COVID‐19 in the US received the investigational nucleotide prodrug remdesivir, supplied on a compassionate basis. 42 Developed as a potential therapy for Ebola, there is in vitro evidence that remdesivir inhibits replication of coronaviruses, including Middle East respiratory syndrome coronavirus and SARS‐CoV‐2. 33 , 43 By late March 2020, four clinical trials to assess the efficacy of remdesivir against COVID‐19 had commenced in the US and two were registered in China. 44 On 29 April, results of the first randomised clinical trial conducted in China were published; 45 while this found no clinical benefit of remdesivir, the trial was underpowered (237 participants) owing to the success of public health measures in controlling COVID‐19 in China. The authors noted a non‐significant numerical reduction in time to clinical improvement in patients commencing treatment earlier in the course of illness.

On 27 May 2020, the first positive results of a randomised double‐blind controlled trial of a treatment for COVID‐19 were published. 46 This international multicentre study reported the preliminary results of 1059 hospitalised patients who received up to 10 days of remdesivir or placebo. Those receiving remdesivir had a significantly shorter median recovery time of 11 days compared with 15 days for those receiving placebo (rate ratio for recovery, 1.32; 95% CI, 1.12–1.55; P  < 0.001); no significant difference in mortality was found. Benefit was reported for the group requiring oxygen but not yet requiring invasive or non‐invasive ventilatory support. This new evidence has led Australian national guidelines to adopt a conditional recommendation for use of remdesivir outside of a trial setting where necessary. 19

Combination therapy with interferon beta‐1b, lopinavir–ritonavir and ribavirin

In May 2020, a randomised trial in Hong Kong reported results of a comparison of lopinavir–ritonavir alone ( n  = 24) with a combination of lopinavir–ritonavir, ribavirin and subcutaneous interferon beta‐1b ( n  = 52). 47 The combination group experienced a faster median time to viral clearance (7 days v 13 days; P  < 0.0001) and shorter median length of hospital stay (8 days v 15 days; P  = 0.0030) if the combination was commenced in the first 7 days from symptom onset. Importantly, the cohort of patients studied was not particularly unwell, with very few requiring ICU support and no deaths in the group.

Immunomodulatory treatments

Corticosteroids.

Interim guidance from the WHO states that corticosteroids should not be used in routine treatment of COVID‐19. 21 This is based on systematic reviews in the context of severe acute respiratory syndrome and Middle East respiratory syndrome which showed lack of effectiveness, and possible harm. 48

In a study of 138 hospitalised patients with COVID‐19 in Wuhan, 49 72.2% of ICU patients and 35.3% of non‐ICU patients received glucocorticoid therapy. The authors commented that while the dose of methylprednisolone varied depending on disease severity, no effective outcomes were observed.

However, on 22 June 2020, a preliminary report regarding interim findings from the UK RECOVERY trial suggested that low dose dexamethasone (6 mg daily orally or intravenous for 10 days) may substantially reduce mortality in hospitalised patients with COVID‐19 who received supplemental oxygen or mechanical ventilation. 50 In comparing 2104 patients randomised to receive dexamethasone with 4321 randomised to receive usual care, dexamethasone was found to reduce mortality by 35% (rate ratio, 0.65; 95% CI, 0.51–0.82; P  < 0.001) among ventilated patients, and for those receiving oxygen without mechanical ventilation, mortality was reduced by 20% (rate ratio, 0.80; 95% CI, 0.70–0.92; P  = 0.002). No benefit of dexamethasone was observed among hospitalised patients who did not require respiratory support. While peer review and formal publication of this analysis is awaited, it is likely that these findings will be reflected in national and international guidelines.

Interleukin 6 antagonists

Tocilizumab is a humanised monoclonal antibody which binds to interleukin 6 (IL‐6) receptors, resulting in reduced immune activation and inflammation. It is licensed in Australia for use in autoimmune conditions including rheumatoid arthritis and giant cell arteritis. In addition to complications of immunosuppression including serious infections, adverse effects include hepatotoxicity and gastrointestinal complications. The theory behind use of tocilizumab or other agents that target the IL‐6 pathway (eg, sarilumab) in the context of COVID‐19 is that part of the pathogenesis in some patients may be attributable to an acute inflammatory syndrome or cytokine storm, which is associated with elevated IL‐6 levels. Clinical trials of these agents are currently underway. 44

Other agents

Numerous immunomodulatory agents have been proposed as potential adjunctive treatments for COVID‐19, with a range of different immunological targets including other inflammatory cytokines. These include anakinra (an IL‐1 receptor antagonist), bevacizumab (an antivascular endothelial growth factor agent), and eculizumab (which inhibits terminal complement and prevents formation of the membrane attack complex). 44 , 51 While clinical trials are underway overseas for several proposed agents, no data exist to support their use at this time. 44

Passive immunotherapy

A preliminary, uncontrolled case series of five critically ill Chinese patients with COVID‐19 who received convalescent plasma containing high SARS‐CoV‐2‐specific antibody titres was published on 27 March 2020. 52 While improvement in clinical status was reported following this intervention, the small sample size and uncontrolled nature of the study precludes drawing any conclusions regarding the efficacy of this intervention. Once again, further research is needed.

Holistic care

A global pandemic causes understandable fear and anxiety for many people in the community. For those at particular risk of worse outcomes of infection — older people and those with significant pre‐existing illness or multiple comorbidities — COVID‐19 represents a particular threat. In addition, the health care workforce is under substantial strain and faces a potentially overwhelming challenge in delivering care to patients. Ensuring emotional care for the most vulnerable and those experiencing high levels of stress will be a fundamental determinant of the resilience of our society during this challenge.

For vulnerable and frail patients at particular risk of poor outcomes, it is important to provide personalised care and to develop an understanding of each individual's perspectives and preferences for health management. Involving caregivers and family members in decision making and establishing goals of care is necessary. 21 Discussing goals of care early and, where appropriate, assisting patients to make advance care directives or resuscitation plans early in illness (or before infection) may provide substantial peace of mind and allow families to face the pandemic openly and with unity as they support vulnerable loved ones.

It is essential to ensure that all patients receive the best standard of care irrespective of the setting in which the care is delivered, or of the existence of any proposed limitations to life‐extending interventions. Under no circumstances should the best possible symptom control and compassionate, individualised care be denied any patient affected by COVID‐19.

SARS‐CoV‐2 has caused a global pandemic with a profound public health impact, changing the daily lives of billions of people. It has exposed weaknesses in even strong and well resourced health systems internationally, and the economic impact alone will be staggering.

However, never before has the global community had the tools currently available to address a pandemic threat. A strong commitment to social and public health strategies and communicable disease control will ensure our health system retains the capacity to address COVID‐19, including sufficient hospital and intensive care resources to care for those with severe illness.

Biomedical innovations such as new and rapid point‐of‐care diagnostics, effective specific treatments and preventive vaccines are very high priorities which are rightly attracting substantial attention and funding. In the interim, high quality, evidence‐based clinical care — scaled up to face the pandemic challenge — together with robust public health interventions will save the lives of thousands in Australia, and millions globally.

Competing interests

No relevant disclosures.

Commissioned; externally peer reviewed.

Acknowledgements

We gratefully acknowledge the contributions of Anna Deng, Louis Irving, Ashleigh Qama and Lien Tran to this article.

The unedited version of this article was published as a preprint on mja.com.au on 8 April 2020

presentation of covid 19 ppt

Please download the file to view it

COVID-19 PowerPoint Presentation on How to Use the Toolkit English

COVID-19 PowerPoint Presentation on How to Use the Toolkit English

In January 2020 the World Health Organization (WHO) declared the outbreak of a new coronavirus disease in Hubei Province, China to be a Public Health Emergency of International Concern. Since then WHO has declared it as a Pandemic affecting more than 115 countries around the globe. India witnessed its first COVID-19 case in Kerala on 30th January 2020. With cases rising steadily, all sections of our society must play a role if we are to stop the spread of this disease and the frontline health worker has the responsibility, the reach and the influence within the community. UNICEF and WHO are supporting the government of India in taking action to contain the COVID-19 outbreak. Towards this UNICEF and WHO developed a training toolkit for training FLWs on COVID response and containment measures. The toolkit consists of this PowerPoint presentation on how to use the FLW Toolkit. This PPT is for Trainers and is a guide on each of the contents that are a part of the FLW Toolkit.

Related Assets

COVID-19 PowerPoint Presentation on How to Use the Toolkit English

161 downloads

presentation of covid 19 ppt

COVID-19 PowerPoint Presentation for FLW Training English

2114 downloads

COVID-19 PowerPoint Presentation for FLW Training English

0 downloads

COVID-19 Pocket Book of Five for ANM, ASHA, AWW English

COVID-19 Pocket Book of Five for ANM, ASHA, AWW English

210 downloads

COVID-19 FACILITATOR GUIDE for Training ANM, ASHA, or AWW English

COVID-19 FACILITATOR GUIDE for Training ANM, ASHA, or AWW English

229 downloads

Request Document

Post feedback.

presentation of covid 19 ppt

  • DynamicPowerPoint.com
  • SignageTube.com
  • SplitFlapTV.com

PresentationPoint

Coronavirus Tips PowerPoint Template

Mar 28, 2020 | Data Dashboards , DataPoint , DataPoint Real-time Screens , Healthcare

To help with the current coronavirus emergency, we have put together these free coronavirus tips Powerpoint slide templates for you to use. The slides include coronavirus prevention tips, symptoms and instructions on what to do if you have symptoms.

Feel free to adjust the templates based on your local health authority instructions and contact information. Download the templates by providing your name and email address below.

Coronavirus Tips – Symptoms

This slide shows the common coronavirus symptoms and gives patients instructions on what to do if they have symptoms so that they don’t go to the hospital or doctor in a panic and overload the local health system. You can edit this slide or add additional slides to add local phone numbers, websites or other resource information.

presentation of covid 19 ppt

nice template

Tạ Đức Huy

I would like to download and amend the COVID slides please.

Solved over chat. Now you can use the presentation. Good luck with it!

Nicole Mcdonald

I would like to download the template as well.

Did you sign up Nicole? That should be working. Check your spam folder maybe.

Millard Collier

Excellent template , I will use for professional and public presentations.

Great to read. Thanks.

Submit a Comment

Your email address will not be published. Required fields are marked *

Pin It on Pinterest

  • StumbleUpon
  • Print Friendly

You are using an outdated browser. Please upgrade your browser to improve your experience.

COVID-19 Templates

The coronavirus outbreak has made this year one of the most unprecedented years of the decade, if not the current century.COVID-19 has impacted businesses massively. Many of the businesses are realigning their strategies and working on change management to address the undesirable business circumstances that have arisen owing to this pandemic. To help businesses show the COVID-19 business impact in an effective manner, we have come up with a collection of COVID-19 Templates ranging from complete business decks to change management templates to risk mitigation templates to stakeholder impact templates and many more. We have also included Free COVID-19 Business Impact Presentation for your reference.

  • Price <= $5.99
  • Price > $5.99

Change Management Theme PowerPoint Template & Google Slides Theme

Change Management Theme PowerPoint Template

Login to use this feature

Add-to-favs lets you build a list for inspiration and future use.

Log in now to start adding your favs.

If you don't have one. A free account also gives you access to our free templates library

Change Management Plan PowerPoint Template & Google Slides Theme

Change Management Plan PowerPoint Template

Digital Business Process Transformation PowerPoint Template & Google Slides Theme

Digital Business Process Transformation PowerPoint Template

COVID-19 Business Impact Presentation PowerPoint Template & Google Slides Theme

COVID-19 Business Impact Presentation PowerPoint Template

Change Management KPI Metrics PowerPoint Template & Google Slides Theme

Change Management KPI Metrics PowerPoint Template

Business Transformation Strategy 1 PowerPoint Template & Google Slides Theme

Business Transformation Strategy 1 PowerPoint Template

Change Management & Implementation PowerPoint Template & Google Slides Theme

Change Management & Implementation PowerPoint Template

Covid 19 Timeline 04 PowerPoint Template & Google Slides Theme

Covid 19 Timeline 04 PowerPoint Template

Risk Assessment & Mitigation Plan PowerPoint Template & Google Slides Theme

Risk Assessment & Mitigation Plan PowerPoint Template

Lessons Learned Feedback PowerPoint Template & Google Slides Theme

Lessons Learned Feedback PowerPoint Template

Risk Mitigation Plan PowerPoint Template & Google Slides Theme

Risk Mitigation Plan PowerPoint Template

BlockChain Pitch Deck Presentation PowerPoint Template & Google Slides Theme

BlockChain Pitch Deck Presentation PowerPoint Template

Covid 19 powerpoint templates for presentations:.

The COVID 19 PowerPoint templates go beyond traditional static slides to make your professional presentations stand out. Given the sleek design and customized features, they can be used as PowerPoint as well as  Google Slides templates . Inculcated with visually appealing unique and creative designs, the templates will double your presentation value in front of your audience. You can browse through a vast library of COVID 19 Google Slides templates,  PowerPoint themes  and  backgrounds  to stand out in your next presentation.

What Is A COVID 19 PowerPoint Template?

A COVID 19 PowerPoint template is a ready-made presentation template that provides a structured framework for creating professional COVID 19 presentations. The COVID 19 PPT presentation template includes design elements, layouts, and fonts that you can customize to fit your content and brand.

What Are The Advantages Of COVID 19 Presentation Templates?

COVID 19 PPT presentation templates can be beneficial because they:

  • Add multiple visual and aesthetic layers to your slides.
  • Ensure that complex information, insights and data is presented in a simplistic way.
  • Enhance the overall visual appeal of the content.
  • Save you a lot of time as you don’t have to start editing from scratch.
  • Improve the professional outlook of your presentation.

How To Choose The Best COVID 19 Presentation Templates?

Keep the following points in mind while choosing a COVID 19 Presentation template for PowerPoint (PPT) or Google Slides:

  • Understand your presentation goals and objectives.
  • Make sure the COVID 19 template aligns with your visual needs and appeal.
  • Ensure the template is versatile enough to adapt to various types of content.
  • Ensure the template is easily customizable.

Can I Edit The Elements In COVID 19 PowerPoint Templates?

Yes, our COVID 19 PowerPoint and Google Slides templates are fully editable. You can easily modify the individual elements including icons, fonts, colors, etc. while making your presentations using  professional PowerPoint templates .

Are COVID 19 PowerPoint Templates Compatible With Google Slides?

Yes, all our COVID 19 presentation templates are compatible and can be used as COVID 19 Google Slides templates.

How To Download COVID 19 PowerPoint Templates For Presentations?

To download COVID 19 presentation templates, you can follow these steps:

  • Select the resolution (16*9 or 4*3).
  • Select the format you want to download the COVID 19 template in (Google Slides or PowerPoint).
  • Make the payment (SlideUpLift has a collection of paid as well as free COVID 19 PowerPoint templates).
  • You can download the file or open it in Google Slides.

Related Presentation Templates

Clinical trials.

7 templates

4 templates

2 templates

282 templates

Patient Journey

8 templates

Forgot Password?

Privacy Overview

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

Got any suggestions?

We want to hear from you! Send us a message and help improve Slidesgo

Top searches

Trending searches

presentation of covid 19 ppt

st patricks day

12 templates

presentation of covid 19 ppt

9 templates

presentation of covid 19 ppt

calendar 2024

35 templates

presentation of covid 19 ppt

environmental protection

8 templates

presentation of covid 19 ppt

sunday school

65 templates

presentation of covid 19 ppt

21 templates

Celebrate Slidesgo’s big 5! Five years of great presentations, faster

COVID-19 Vaccine Breakthrough

Covid-19 vaccine breakthrough presentation, free google slides theme and powerpoint template.

Aren't you tired of COVID-19? Great news: vaccines are already here! Use this new editable template to tell your audience all the latest discoveries on the matter. Since blue is the color of safety, we've used it to set the right atmosphere. We've used other resources, such as illustrations of syringes, viruses and people, and even icons to enhance the layouts and help you reinforce your points. Use the graphs, tables and infographics supplied to reflect the data properly so that everyone understands it at a glance!

Features of this template

  • 100% editable and easy to modify
  • 27 different slides to impress your audience
  • Contains easy-to-edit graphics such as graphs, maps, tables, timelines and mockups
  • Includes 500+ icons and Flaticon’s extension for customizing your slides
  • Designed to be used in Google Slides and Microsoft PowerPoint
  • 16:9 widescreen format suitable for all types of screens
  • Includes information about fonts, colors, and credits of the free resources used

How can I use the template?

Am I free to use the templates?

How to attribute?

Attribution required

Related posts on our blog.

How to Add, Duplicate, Move, Delete or Hide Slides in Google Slides | Quick Tips & Tutorial for your presentations

How to Add, Duplicate, Move, Delete or Hide Slides in Google Slides

How to Change Layouts in PowerPoint | Quick Tips & Tutorial for your presentations

How to Change Layouts in PowerPoint

How to Change the Slide Size in Google Slides | Quick Tips & Tutorial for your presentations

How to Change the Slide Size in Google Slides

Related presentations.

COVID-19 Vaccine Research presentation template

Premium template

Unlock this template and gain unlimited access

Brands Response to COVID-19 presentation template

IMAGES

  1. Covid-19 Coronavirus

    presentation of covid 19 ppt

  2. Free Infographics COVID-19 PowerPoint

    presentation of covid 19 ppt

  3. Try a Stunning Coronavirus PowerPoint Template Presentation

    presentation of covid 19 ppt

  4. Covid-19 Virus

    presentation of covid 19 ppt

  5. COVID-19

    presentation of covid 19 ppt

  6. Covid-19 PPT Business

    presentation of covid 19 ppt

VIDEO

  1. Information About Corona Virus Covid 19

  2. Genexya Presentation

  3. GMGA 1013

  4. How to recolor a graphic object in covid-19 PPT

  5. COVID 19 Presentation

COMMENTS

  1. COVID-19 presentation for educators

    All images included in this presentation are in the public domain. [email protected] This presentation summarizes important basic information on the current pandemic. It was written for...

  2. COVID-19 Google Slides Theme and PowerPoint Template

    COVID-19 Presentation Premium Google Slides theme and PowerPoint template The coronavirus outbreak has become one of the most notorious events of the decade, if not the current century. Every bit of information helps a lot, so let us help you create useful and informative presentations about this virus with our latest template.

  3. Best Free Covid Coronavirus & Virus PowerPoint PPT Templates 2022

    Covid-19 Virus - Medical PowerPoint Template The Covid-19 is a medical PowerPoint template with more than 70 unique and modern slides. This Covid presentation template has a gorgeous duotone color scheme, but you can easily customize it to match your brand. You'll also find unique mockup devices, image placeholders, infographic elements, and more.

  4. PDF Updates to COVID-19 Testing and Treatment for the Current SARS ...

    What Clinicians Need to Know About the New Oral Antiviral Medications for COVID-19 Centers for Disease Control and Prevention Center for Preparedness and Response Updates to COVID-19 Testing and Treatment for the Current SARS-CoV-2 Variants Clinician Outreach and Communication Activity (COCA) Call Tuesday, January 24, 2023 Continuing Education

  5. PPTX CDC Presentation

    This is a PowerPoint presentation from the CDC's Clinician Outreach and Communication Activity (COCA) on the novel coronavirus (2019-nCoV) outbreak. It provides an overview of the epidemiology, clinical features, infection prevention and control, and guidance for clinicians. It also includes links to additional resources and updates from the CDC and the World Health Organization (WHO).

  6. PPTX PowerPoint Presentation

    SARS-CoV-2 is the official, scientific name of the virus, the germ that causes the disease COVID-19. COVID-19 is the name of the disease - the fever, cough, chills and other symptoms that people have when they are infected with the virus SARS-CoV-2. Genes that contain all the information needed to make more virus copies.

  7. Coronavirus Google Slides themes and PowerPoint templates

    Coronavirus Google Slides themes and PowerPoint templates Celebrate Slidesgo's big 5! Five years of great presentations, faster Let's party Coronavirus Presentation templates Raise awareness about one of the hottest topics of the 21st century by downloading and editing our free PPT templates and Google Slides themes about Coronavirus. Filters Ads

  8. PDF Underlying Medical Conditions and Severe COVID-19: Evidence-based ...

    Daily number of COVID-19 death reported to CDC and 7-day cumulative incidence rate (per 100,000 Population), United States, Jan. 2020-May 2021. Total deaths in the US: 587,342. 7-Day Moving Average: 500. Blue bars — number of daily deaths.

  9. Tool 4. Presentation template

    Presentation template - 28 April 2021. 28 April 2021. | COVID-19: Critical preparedness, readiness and response. Download (3.8 MB)

  10. Economic Impact of Coronavirus Google Slides & PPT Template

    Economic Impact of Coronavirus Presentation Free Google Slides theme and PowerPoint template The recent coronavirus pandemic has forced many businesses and industries to stop their activities until society can start resuming a normal life again. This, in turn, is causing an economic impact on most countries.

  11. Clinical presentation and management of COVID‐19

    Treatment for COVID ‐19 is currently predominantly supportive care, focused on appropriate management of respiratory dysfunction. Clinical evidence is emerging for some specific therapies (including antiviral and immune‐modulating agents).

  12. COVID-19 PowerPoint Presentation for FLW Training English

    The toolkit consists of this PowerPoint presentation to be used by the designated COVID-19 trainers. The trainer should conduct the training using the PPT which has all the sessions to be covered d. In January 2020 the World Health Organization (WHO) declared the outbreak of a new coronavirus disease in Hubei Province, China to be a Public ...

  13. Lessons Learned about COVID-19

    Lessons Learned about COVID-19 Presentation Free Google Slides theme and PowerPoint template After a year and a half, has society really learned a lesson about the COVID-19 pandemic? What about in education? These are questions that you can answer by customizing this new template for educational presentations.

  14. Free COVID (Coronavirus)-19 Impact PowerPoint Template

    Covid-19 PPT Template: Download our free Coronavirus Impact PowerPoint Template with amazing design to create informative presentations. These covid19 ppt templates are 100% editable, totally customized, easily downloadable, and ready to use.

  15. COVID-19 PowerPoint Presentation on How to Use the Toolkit English

    Please download the file to view it COVID-19 PowerPoint Presentation on How to Use the Toolkit English In January 2020 the World Health Organization (WHO) declared the outbreak of a new coronavirus disease in Hubei Province, China to be a Public Health Emergency of International Concern.

  16. Coronavirus Tips PowerPoint Template • PresentationPoint

    To help with the current coronavirus emergency, we have put together these free coronavirus tips Powerpoint slide templates for you to use. The slides include coronavirus prevention tips, symptoms and instructions on what to do if you have symptoms. Feel free to adjust the templates based on your local health authority instructions and contact ...

  17. 1004+ Free Editable COVID-19 Templates for PowerPoint

    To help businesses show the COVID-19 business impact in an effective manner, we have come up with a collection of COVID-19 Templates ranging from complete business decks to change management templates to risk mitigation templates to stakeholder impact templates and many more.

  18. PDF PowerPoint Presentation

    Impacted by Anxiety and Depression. Since the beginning of the worry about COVID-19 in mid-to-late February, there have been at least 88,405 additional positive depression and anxiety screening results over what had been expected (using November 2019-January 2020 average as a baseline). There have been 54,093 additional moderate to severe ...

  19. PPTX PowerPoint Presentation

    new developments in COVID-19 vaccination, the epidemiological context, or the schedule or characteristics of vaccine products in use. insufficient uptake or demand among high-priority groups. needs to scale up the capability, efficiency, or sustainability of the country's health system ... PowerPoint Presentation Last modified by:

  20. PDF Treating Long COVID: Clinician Experience with Post-Acute COVID-19 Care

    The presentation will not include any discussion of the unlabeled use of a product or a product under investigational use. ... acute COVID-19 illness or symptoms that resolved and reappeared1 -9% reported prolonged symptoms as severe2 1. Salmon-Ceron et al., J Infect. 2020 2. Petersen et al., Clin Infect Dis. 2020

  21. Free Linear COVID-19 Prevention for Google Slides and PPT

    Linear COVID-19 Prevention Free Google Slides theme and PowerPoint template Currently, all information concerning preventive measures against COVID-19 is crucial and should be accessible for everybody. Explain them in the form of infographics, since images convey a lot.

  22. PPTX PowerPoint Presentation

    the estimated wastage rate of available COVID-19 vaccine products.** Step 2: Calculate requirements. Revisit. and update COVID-19 vaccine estimates based on product specifications and supply allocations at the subnational level. * As with other vaccines, the requirement of COVID-19 vaccine doses is calculated in terms of "number of doses".

  23. COVID-19 Vaccine Breakthrough

    Free Google Slides theme and PowerPoint template Aren't you tired of COVID-19? Great news: vaccines are already here! Use this new editable template to tell your audience all the latest discoveries on the matter. Since blue is the color of safety, we've used it to set the right atmosphere.